Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.

Guy M Goodwin,Scott T Aaronson,Oscar Alvarez,Merve Atli,James C Bennett,Megan Croal,Charles DeBattista,Boadie W Dunlop,David Feifel,David J Hellerstein,Muhammad Ishrat Husain,John R Kelly,Molly R Lennard-Jones,Rasmus W Licht,Lindsey Marwood,Sunil Mistry,Tomáš Páleníček, Ozlem Redjep,Dimitris Repantis,Robert A Schoevers, Batya Septimus,Hollie J Simmons,Jair C Soares,Metten Somers,Susan C Stansfield, Jessica R Stuart, Hannah H Tadley, Nisha K Thiara,Joyce Tsai,Mourad Wahba,Sam Williams, Rachel I Winzer,Allan H Young, Matthew B Young,Sid Zisook,Ekaterina Malievskaia

Journal of affective disorders（2023）

引用 17|浏览41

暂无评分

摘要

Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.

查看译文

关键词

Antidepressant,Anxiety,Patient-reported outcomes,Psilocybin,Psychedelic,Treatment-resistant depression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要